rs1042522
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
SNP309 T alleles were associated with a significantly decreased prostate cancer risk among Pro72Arg Pro </span>alleles carriers (OR=0.79, 95% CI, 0.64-0.98).
|
26025918 |
2016 |
rs1042522
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients.
|
25213701 |
2014 |
rs1042522
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
This study shows that the overall risk of prostate cancer was not associated with Arg72Pro SNP and HPV infection in our cohort.
|
21778786 |
2011 |
rs1042522
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Our study provided evidence that the P53 intron 6 G>A and R72P G>C polymorphisms were associated with a higher risk of prostate cancer in a Northern Indian population.
|
21565625 |
2011 |
rs1042522
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
p53 Pro72Arg polymorphism and prostate cancer in men of African descent.
|
20593380 |
2010 |
rs1042522
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Although we did not find a significant relationship between the frequency of the Arg/Pro + Pro/Pro genotype of p53 Arg72Pro and susceptibility in PC, there was a combined effect of CXCL12 GA + AA genotype and the p53 72Arg/Pro + Pro/Pro genotype on the frequency of PC.
|
17785557 |
2007 |
rs1131691014
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
SNP309 T alleles were associated with a significantly decreased prostate cancer risk among Pro72Arg Pro </span>alleles carriers (OR=0.79, 95% CI, 0.64-0.98).
|
26025918 |
2016 |
rs1131691014
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients.
|
25213701 |
2014 |
rs1131691014
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Our study provided evidence that the P53 intron 6 G>A and R72P G>C polymorphisms were associated with a higher risk of prostate cancer in a Northern Indian population.
|
21565625 |
2011 |
rs1131691014
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
This study shows that the overall risk of prostate cancer was not associated with Arg72Pro SNP and HPV infection in our cohort.
|
21778786 |
2011 |
rs1131691014
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
p53 Pro72Arg polymorphism and prostate cancer in men of African descent.
|
20593380 |
2010 |
rs1131691014
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Although we did not find a significant relationship between the frequency of the Arg/Pro + Pro/Pro genotype of p53 Arg72Pro and susceptibility in PC, there was a combined effect of CXCL12 GA + AA genotype and the p53 72Arg/Pro + Pro/Pro genotype on the frequency of PC.
|
17785557 |
2007 |
rs878854066
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
SNP309 T alleles were associated with a significantly decreased prostate cancer risk among Pro72Arg Pro </span>alleles carriers (OR=0.79, 95% CI, 0.64-0.98).
|
26025918 |
2016 |
rs878854066
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients.
|
25213701 |
2014 |
rs878854066
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
This study shows that the overall risk of prostate cancer was not associated with Arg72Pro SNP and HPV infection in our cohort.
|
21778786 |
2011 |
rs878854066
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Our study provided evidence that the P53 intron 6 G>A and R72P G>C polymorphisms were associated with a higher risk of prostate cancer in a Northern Indian population.
|
21565625 |
2011 |
rs878854066
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
p53 Pro72Arg polymorphism and prostate cancer in men of African descent.
|
20593380 |
2010 |
rs878854066
|
|
Prostate carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Although we did not find a significant relationship between the frequency of the Arg/Pro + Pro/Pro genotype of p53 Arg72Pro and susceptibility in PC, there was a combined effect of CXCL12 GA + AA genotype and the p53 72Arg/Pro + Pro/Pro genotype on the frequency of PC.
|
17785557 |
2007 |
rs138983188
|
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Id4 was over-expressed in prostate cancer cell line DU145 harboring mutant p53 (P223L and V274F) and silenced in LNCaP cells with wild type p53.
|
24330748 |
2013 |
rs138983188
|
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
These results provide first evidence to implicate the functional Pro64His variant of galectin-3 (LGALS3) in the genetic susceptibility towards prostate cancer.
|
21396839 |
2013 |
rs1057520005
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Id4 was over-expressed in prostate cancer cell line DU145 harboring mutant p53 (P223L and V274F) and silenced in LNCaP cells with wild type p53.
|
24330748 |
2013 |
rs1060501201
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We identified 101 heterozygous carriers of G84E who underwent radical prostatectomy for prostate cancer between 1985 and 2011 and matched these men by race, age and tumor grade to 99 HOXB13 wild-type controls.
|
28186998 |
2017 |
rs143458271
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our study provided evidence that the P53 intron 6 G>A and R72P G>C polymorphisms were associated with a higher risk of prostate cancer in a Northern Indian population.
|
21565625 |
2011 |
rs267605077
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Three prostate cancer-derived p53 mutants (F134L, M237L, R273H) were introduced into LNCaP prostate cancer cells and stable transfectants established.
|
14587098 |
2003 |
rs28934576
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Targeting CD24 provides a strategy to enhance mutant p53-restoring therapies, especially in patients with TP53(R273H) prostate cancer.
|
26712693 |
2016 |